Evidence map›Paper›PMID 41816792›Full record

ReviewFrontiers in genetics2026

Unravelling the genetic architecture of cardiovascular disease through structural variant detection with whole-genome sequencing.

Dona N P Colombage, Eric K Moses, Phillip E Melton

Abstract readReview
In one paragraph

Review in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dona N P ColombageMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Eric K MosesMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Phillip E MeltonMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) remains the leading cause of worldwide morbidity and mortality. Studies have found that there is a significant genetic component contributing to CVD development. Advances in genome sequencing technologies have revolutionized the identification of disease-causing variants in the human genome. With the development of whole genome sequencing (WGS), the understanding of these variants has been deepened as it enables comprehensive detection of many variants in the genome including structural variants (SVs). SVs are large genomic variants that are present in the genome of an organism and play a significant role in disease. Numerous techniques are being used to detect SVs with varying accuracy levels. Due to the limited number of focused research studies on SVs and CVD, there is a rich opportunity for further investigation with the aim of utilizing SV data in disease diagnosis and treatment plans. Emerging evidence highlights the role of SVs in CVD and the importance of adopting WGS approaches to unravel the genetic architecture of CVD. Moreover, integrating SV data with population scale epidemiology and advanced risk prediction models would enhance CVD prevention by enabling more personalized treatment strategies. This review aims to describe the different types of SVs and their involvement in CVD development and then to discuss WGS-based SV detection methods and future clinical implementations. We also report an overview of the SVs identified across various CVD types and different bioinformatics tools that can be used to detect SVs in WGS data.

Indexed as

bioinformaticscardiovascular diseasegenome medicinemobile elementsstructural variantswhole genome sequencing

Identifiers

PMID41816792
PMCPMC12975141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.